Two new hepatitis C therapies fast-tracked in Europe

Two drug combinations from Gilead and AbbVie that could improve treatment of chronic hepatitis C have been granted accelerated review in the EU. Gilead's application is for a three drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir – given over 12 weeks – that could achieve a cure for chronic hepatitis C virus (HCV) patients who have failed other regimens. The new direc

Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C

 97.5 percent of chronic HCV infected patients without cirrhosis and new to treatment across all major genotypes (GT1-6) achieved SVR12 with 8 weeks of G/P Across the 8-week arms of three registrational studies, no patients discontinued treatment due to adverse events G/P is an investigational, pan-genotypic, once-daily, ribavirin-free regimen for the treatment of chronic HCV NORTH CHICAGO, Ill., Nov. 11, 2016 /PRNewswire/ -- AbbVie (N...